pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,573 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1774Endpoints1383Fierce Biotech702BioSpace694BioPharma Dive523raps231onclive165fda recalls111fda medwatch
therapy area
allOncology12291Rare Disease3188Immunology2860Cardiology2725Hematology2167Pulmonology2136Vaccines
  • Doritos market themselves as farm-to-table despite being ultra-processed, highlighting industry image push
    Doritos' latest ads portray the nacho cheese snack as a farm-to-table product, showing corn seedlings and a farmer in a PepsiCo hat and claiming a partnership with farmers to bring the chips from f…
    STAT · 2mo agoNegative↗ source
  • FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
    Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
    BioPharma Dive · 2mo agoApprovalPositive↗ source
← prev
page 45 of 103
next →
109
globenewswire health73
fda press59
1794
Psychiatry & CNS1200
Ophthalmology1049
Endocrinology & Metabolism775
Pain773
Nephrology759
  • Argenx reports positive Phase 3 results for Vyvgart Hytrulo in myositis
    Argenx announced that its subcutaneous formulation of Vyvgart, named Vyvgart Hytrulo, met the primary endpoint in a late‑stage Phase 3 trial in patients with myositis. The trial combined participa…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Eyepoint's wet AMD therapy misses primary goal in Phase 3, stock tumbles
    Eyepoint reported that its experimental drug Duravyu did not keep vision in patients with wet age-related macular degeneration when given less frequently than the standard of care, causing the Phas…
    STAT · 2mo agoNegative readoutNegative↗ source
  • EyePoint shares tumble as Durayvu misses primary goal in wet AMD trial
    EyePoint, a Boston biotech, saw its market value drop by nearly $1 billion after its lead candidate Durayvu failed to demonstrate non-inferiority to aflibercept in a pivotal phase 3 trial for wet a…
    BioPharma Dive · 2mo agoNegative readoutNegative↗ source
  • AstraZeneca halts Phase 3 lung cancer trial of bispecific antibody volrustomig after interim data miss survival goal
    AstraZeneca announced termination of the Phase 3 study of its experimental bispecific antibody volrustomig in non‑small cell lung cancer. An interim data review by trial monitors indicated the dru…
    BioPharma Dive · 2mo agoNegative readoutNegative↗ source
  • Sanofi to cut 229 Massachusetts jobs a year after $9.1 billion Blueprint Medicines acquisition
    Sanofi announced it will lay off 229 employees in Massachusetts, according to a filing with the state's Executive Office of Labor and Workforce Development. The workers are from Blueprint Medicine…
    STAT · 2mo agoLayoffsNegative↗ source
  • IRS probes UnitedHealth tax filings and private-equity deals for doctor groups slow down
    UnitedHealth disclosed that the IRS has opened an investigation into its tax filings for 2017-2020, seeking to increase the company’s taxable income and potentially raise its tax bill for those yea…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Akeso and Summit’s lung cancer candidate shows worsening tumor progression, while Europe halts Tavneos over trial concerns
    Akeso Therapeutics and Summit Therapeutics reported that their combined lung cancer therapy failed to improve outcomes, with data indicating a worsening in tumor progression compared to control. T…
    STAT · 2mo agoNegative readoutNegative↗ source
  • AstraZeneca halts late-stage trial of volrustomig in metastatic lung cancer
    AstraZeneca said it is stopping a late-stage study of its experimental drug volrustomig combined with chemotherapy in patients with metastatic non-small cell lung cancer. The company made the decis…
    STAT · 2mo agoNegative↗ source
  • Epic faces antitrust lawsuits and internal AI strategy turmoil ahead of annual user meeting
    Epic Systems, founded by Judy Faulkner, dominates the U.S. hospital electronic health record market and convenes its annual User Group Meeting with more than 20,000 attendees. The upcoming gatheri…
    STAT · 2mo agoRegulatoryNegative↗ source
  • IRS launches probe into UnitedHealth over alleged tax avoidance from 2017-2020
    UnitedHealth Group is under investigation by the Internal Revenue Service, which says the insurer underpaid taxes by moving money to a foreign subsidiary during 2017-2020. The IRS is seeking to in…
    STAT · 2mo agoRegulatoryNegative↗ source
  • North Carolina’s bipartisan Medicaid pilot shows social services can cut health costs
    The article, written by former state health secretaries Mandy Cohen and Kody Kinsley, says North Carolina’s health‑care affordability crisis was tackled through a bipartisan pilot. The Healthy Opp…
    STAT · 2mo agoPositive↗ source
  • State Laws Cut Private-Equity Acquisitions of Physician Practice Management Firms in Half
    State regulators in more than a dozen states have enacted laws that tighten oversight of private‑equity deals in health care, according to a new report. The tighter rules are reported to be slowing…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Trump administration issues executive order overhauling federal vaccine program, drawing WHO criticism
    President Trump signed an executive order on Monday that reshapes the federal vaccine agenda, proposing changes that officials say lack supporting evidence. The World Health Organization publicly…
    STAT · 2mo agoRegulatoryNegative↗ source
  • RFK Jr. contrasts vaccine push in D.C. with addiction-treatment focus in California
    In Washington, the health secretary stood beside the president as an executive order was signed to overhaul childhood vaccination policy. The scene highlighted his push for broader vaccine adoption…
    STAT · 2mo agoNeutral↗ source
  • Slate Medicines to merge with Fulcrum Therapeutics after Fulcrum drops sickle-cell drug
    Slate Medicines announced it will combine with Fulcrum Therapeutics in a reverse merger, giving the struggling biotech a new corporate home. Fulcrum had been developing pociredir, a therapy design…
    BioPharma Dive · 2mo agoDealNegative↗ source
  • Oma's Pride recalls one lot of 6 lb Woof Complete canine chicken food after Salmonella contamination
    Oma's Pride of Avon, Connecticut, announced a voluntary recall of a single lot (BB012729) of its 6‑lb Woof Complete Canine Chicken Recipe pet food after testing revealed Salmonella contamination.…
    fda recalls · 2mo agoCRLNeutral↗ source
  • Paid paternity leave framed as preventive pediatric care in new opinion piece
    Pediatrician Nishant Pandya shares a recent clinic scene where a new father had to return to work the day after his daughter’s birth, highlighting the tension many families face. He notes that whi…
    STAT · 2mo agoPositive↗ source
  • FDA approves Bristol Myers' first oral therapy for advanced multiple myeloma, a new drug class
    The U.S. Food and Drug Administration gave its nod to an oral medication from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug represents the first member of a novel clas…
    STAT · 2mo agoApprovalPositive↗ source
  • FDA clears Bristol Myers' Zenbexus, first drug of a new class for advanced multiple myeloma
    The FDA announced approval of an oral therapy from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug, iberdomide, will be marketed as Zenbexus and is intended to be used t…
    STAT · 2mo agoApprovalPositive↗ source
  • Capricor shares jump as FDA signals openness to review updated Duchenne therapy
    Capricor Therapeutics saw its stock rise sharply after CEO Linda Marbán told analysts that the FDA is willing to look at an amended filing for its Duchenne muscular dystrophy cell therapy, deramioc…
    BioPharma Dive · 2mo agoRegulatoryPositive↗ source
  • FDA grants accelerated approval to Bristol's Zenbexus for multiple myeloma; PBMs adopt TrumpRx pricing; Novartis wins UK Entresto patent
    The U.S. Food and Drug Administration granted accelerated approval to Bristol Myers Squibb's oral therapy Zenbexus for patients with advanced multiple myeloma. The drug represents a new class of tr…
    STAT · 2mo agoApprovalPositive↗ source
  • FDA grants accelerated approval to Bristol Myers' Zenbexus, first CELMoD for multiple myeloma
    The FDA issued an accelerated approval on Thursday for Zenbexus, a multiple myeloma therapy that Bristol Myers Squibb inherited from its Celgene acquisition. Zenbexus belongs to a new class of pro…
    BioPharma Dive · 2mo agoApprovalPositive↗ source
  • Drug-testing lab sues US Pharmacopeia over alleged false statements about testing methods
    Valisure, a laboratory known for testing drug impurities, has filed a lawsuit in a U.S. court accusing the United States Pharmacopeia (USP) of making false and misleading statements about its testi…
    STAT · 2mo agoRegulatoryNegative↗ source